More importantly, we demonstrated that caspase-1 inhibition with VX-765, a potent bioavailable and nontoxic small molecule inhibitor of caspase‐1 (25), downregulated the NLRP3 inflammasome, reduced lung inflammation, decreased pyroptosis-mediated cell death, increased cell proliferation, improved alveolarization and vascular development, and reduced pulmonary fibrosis in hyperoxia-exposed mice. The gene discussed is NLRP3; the disease is pulmonary fibrosis.